IP Insider
Bayer Sues in U.S. to Stop India Generic Drug Co.
A subsidiary of Bayer AG has filed suit in federal court in Wilmington, Delaware, against Glenmark Generics, seeking to stop the Mumbai-based company from selling a generic form of a medication used to treat a skin disorder.
Supreme Court Strengthens First-Sale Doctrine in 6-3 Vote
Libraries, museums, retailers and others who buy copyrighted goods made abroad can resell them without violating federal copyright law, the U.S. Supreme Court ruled on Tuesday.
Making Choices to Protect Against Trade Secret Theft
As corporations face more threats to their networks and trade secrets, former U.S. Department of Homeland Security Secretary Michael Chertoff has this piece of advice: "What you really want to ask yourself is, What do I want to protect?"
Pharma, Biotech IP Counsel Expect a Litigious Year
In a survey by Consero Group, nearly half of chief IP counsel from the pharmaceutical and biotech industries said that their companies are involved in patent infringement litigation—and 43 percent said there was a "very high" likelihood they would file a patent claim in the year ahead.
Change in Law Triggering Race to Patent Office
As the final pieces of the America Invents Act are about to go into effect March 16, intellectual property lawyers are scrambling to get thousands of last-minute patent filings in before the old rules expire Friday.
ICANN Domain Expansion Means More Work to Protect Brands Online
The Internet's address system is about to undergo its largest expansion since its creation—a change that will force companies to do more work and spend more money to protect their brands.
A Little-Publicized Change in Patent Law on Secret Prior Art
Among the many changes in U.S. patent law under the Leahy-Smith America Invents Act, the elimination of secret prior art has received little attention.
Proving Obviousness in Patent Cases
Proving obviousness in patent litigation requires proof. Careful litigants form their obviousness theories early in the case and develop the factual record to support those theories.
India Patent Ruling on Cancer Drug a Blow to Bayer AG
India's patent appeals board ruled that a domestic generic drug maker could continue to make and sell a low-priced copy of Nexavar, a cancer medication patented by Bayer AG.
$1B-Plus IP Awards Lead Top Verdicts of 2012
Intellectual property verdicts represented the largest category in number and dollar value last year. The category has contributed one verdict higher than $1 billion in each of the three prior years. But this year's list of top verdicts was notable in that three verdicts reached the $1 billion mark or higher, and all of them came out of high-stakes trials.
Corporate Counsel Membership Program
Receive exclusive offers and discounts today!
- Digital editions of Corporate Counsel Magazine
- Corporate Counsel eNewsletters
- Discounts on books, events, online CLE and research
